1996
DOI: 10.1016/s0009-9236(96)90177-0
|View full text |Cite
|
Sign up to set email alerts
|

Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism*

Abstract: These results show that the small intestine can be a major site for presystemic, CYP3A-mediated metabolism after oral administration. Moreover, it appears that this represents a true first-pass effect. In addition, intestinal and hepatic metabolism may be important factors in interindividual variability in disposition after oral administration of midazolam and similar CYP3A substrates. Finally, intestinal localization of CYP3A may be significant in metabolism-based drug-drug interactions.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

42
435
5

Year Published

1998
1998
2015
2015

Publication Types

Select...
6
4

Relationship

0
10

Authors

Journals

citations
Cited by 542 publications
(482 citation statements)
references
References 25 publications
42
435
5
Order By: Relevance
“…The BA of midazolam in humans was previously reported to be 30.0% [61]. The BA of midazolam in microminipigs was similar to that in humans, while the CL int values in the other animals were within approximately ± 3-fold that in humans.…”
Section: Discussionsupporting
confidence: 66%
“…The BA of midazolam in humans was previously reported to be 30.0% [61]. The BA of midazolam in microminipigs was similar to that in humans, while the CL int values in the other animals were within approximately ± 3-fold that in humans.…”
Section: Discussionsupporting
confidence: 66%
“…Since C max and AUC are direct indicators of the extent of absorption, the observed increases in these parameters supports the idea that in birds that died, zero-order metabolism was occurring. Similar increases in AUC and C max have been described for midazolam in humans, and this was reportedly linked to saturation of the presystemic elimination pathways (Bornemann et al 1985;Thummel et al 1996).…”
Section: Discussionsupporting
confidence: 70%
“…The interindividual variability contributes to the variability in blood levels of orally administered drugs that are substrates of CYP3A4. [13][14][15][16] Mucosal CYP3A4 activity can be inhibited by grapefruit juice and occurs probably instantaneously. In a human volunteer, mucosal CYP3A4 activity estimated in mucosal biopsies taken 4 hr after grapefruit juice was administered decreased 47%.…”
Section: Discussionmentioning
confidence: 99%